A Agilent receives EU approval for pd-l1 ihc 22c3 pharmdx in epithelial ovarian, fallopian tube, or primary peritoneal carcinoma Agilent Tec
A Agilent receives EU approval for pd-l1 ihc 22c3 pharmdx in epithelial ovarian, fallopian tube, or primary peritoneal carcinoma Agilent Technologies - approval expands pd-l1 testing to support Keytruda treatment decisions
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.